-- 根據彭博社週四援引公司和業內消息人士報道，Meta Platforms (META) 首席執行官馬克·扎克伯格和蘋果公司 (AAPL) 首席執行官蒂姆·庫克並未計劃競購美國國家橄欖球聯盟 (NFL) 的西雅圖海鷹隊。 報道稱，Meta 的發言人表示，祖克柏沒有對該球隊進行任何投資或競購，而一位熟悉庫克計畫的人士則否認了他參與此事。 Meta 和蘋果公司均未立即回覆的置評請求。 （市場閒談新聞來自與全球市場專業人士的對話。這些資訊據信來自可靠來源，但可能包含傳聞和猜測。準確性無法保證。）
Price: $616.43, Change: $-52.69, Percent Change: -7.87%
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.